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a b s t r a c t
Vaginal rings are currently being developed for the long-term (at least 30 days) continuous delivery of
microbicides against human immunodeﬁciency virus (HIV). Research to date has mostly focused on
devices containing a single antiretroviral compound, exempliﬁed by the 25 mg dapivirine ring currently
being evaluated in a Phase III clinical study. However, there is a strong clinical rationale for combining
antiretrovirals with different mechanisms of action in a bid to increase breadth of protection and limit
the emergence of resistant strains. Here we report the development of a combination antiretroviral sili-
cone elastomer matrix-type vaginal ring for simultaneous controlled release of dapivirine, a non-nucle-
oside reverse transcriptase inhibitor, and maraviroc, a CCR5-targeted HIV-1 entry inhibitor. Vaginal rings
loaded with 25 mg dapivirine and various quantities of maraviroc (50–400 mg) were manufactured and
in vitro release assessed. The 25 mg dapivirine and 100 mg maraviroc formulation was selected for fur-
ther study. A 24-month pharmaceutical stability evaluation was conducted, indicating good product sta-
bility in terms of in vitro release, content assay, mechanical properties and related substances. This
combination ring product has now progressed to Phase I clinical testing.
 2012 Elsevier B.V. All rights reserved.
1. Introduction
In the last decade, increased access to highly active antiretrovi-
ral therapy has led to a decline in the number of new HIV infections
occurring annually (3.1 million in 2001, 2.7 million in 2010) and
signiﬁcantly increased life expectancy for infected individuals
(UNAIDS, 2010; WHO, UNAIDS and UNICEF, 2011). The positive im-
pact of antiretroviral drugs on the treatment of HIV infection has
spurred interest in their potential for preventing sexual transmis-
sion of human immunodeﬁciency virus (HIV), with promising re-
sults obtained following both oral (Cohen et al., 2011; Grant
et al., 2010) and vaginal (Abdool Karim et al., 2010) administration.
In the context of HIV prophylaxis, a topical microbicide is a
vaginally or rectally administered product designed to prevent
HIV transmission across the relevant mucosal tissue (Fetherston
et al., 2010; Garg et al., 2009; Kelly et al., 2011; Nuttall et al.,
2010; Romano et al., 2008; Shattock et al., 2004; Stone and
Harrison, 2010; Woolfson et al., 2006a). Antiretroviral-based
microbicide products are now being developed and various animal
studies have demonstrated some degree of efﬁcacy (Caron et al.,
2010; Fetherston et al., in press; Lederman et al., 2004; Malcolm
et al., in press; Neff et al., 2011; Singer et al., 2012; Stolte-Leeb
et al., 2011; Veazey et al., 2005a, 2010). Results from the CAPRISA
004 study, the ﬁrst human clinical trial to assess efﬁcacy of a vag-
inally administered ARV microbicide product (Abdool Karim et al.,
2010), demonstrated that coitally-related twice daily application of
1.0% tenofovir vaginal gel reduced HIV transmission to women by
39% and by up to 54% in high adherence users. Unfortunately, re-
cent data from the VOICE (Vaginal and Oral Interventions to Con-
trol the Epidemic) trial indicated that once daily administration
of tenofovir, either orally (tablet) or vaginally (gel), was not effec-
tive in protecting women from sexually acquired HIV infection.
Although the formulations were found to be safe in use, both arms
of the trial were discontinued due to futility. Evaluation of once
daily Truvada (a combination of emtricitabine and tenofovir diso-
proxil fumarate for oral administration) is continuing. Other lead
candidate antiretroviral compounds being developed as HIV micro-
bicides include dapivirine (an experimental, small molecule non-
nucleoside reverse transcriptase inhibitor, NNRTI), and maraviroc
(a small molecule CCR5-targeted HIV-1 entry inhibitor) (Dorr
et al., 2005; MacArthur and Novak, 2008). Vaginally administered
gels (Nel et al., 2009b, 2010a,b), rings (Gupta et al., 2008; Johnson
et al., 2010; Malcolm et al., 2005; Nel et al., 2009a; Woolfson et al.,
2006b) and ﬁlm formulations (Akil et al., 2011) containing
dapivirine have been described previously. For maraviroc, which
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is currently used as part of oral antiretroviral therapy to reduce vir-
al load in infected people, various vaginal gel and ring formulations
have been evaluated as potential microbicide strategies (Forbes
et al., 2011; Malcolm et al., 2012a, in press; Neff et al., 2011; Vea-
zey et al., 2010).
Given the ongoing concerns with adherence to prescribed use
regimes (Abdool Karim et al., 2010), a single application microbi-
cide product that provides continuous microbicide delivery over
a long time period is likely to be more effective than one adminis-
tered pericoitally (e.g. gels). Vaginal rings are being developed for
the controlled delivery of one or more HIV microbicides to the va-
gina (Fetherston et al., 2010, in press; Han et al., 2007; Johnson
et al., 2010; Kaur et al., 2011; Malcolm et al., 2005, 2010, 2012a;
Moss et al., 2012; Nel et al., 2009a; Romano et al., 2009; Saxena
et al., 2009; Singer et al., 2012; Woolfson et al., 2006a, 2006b).
Use of such devices is female-initiated, which may prove useful
in reducing sexual HIV transmission in women. Vaginal rings offer
a number of advantages to users over conventional gel formula-
tions, such as a longer duration of action, reduced dosing intervals,
continuous placement and the possibility of covert use (Fetherston
et al., 2010; Malcolm et al., 2010; Woolfson et al., 2006a).
The most clinically advanced microbicide-releasing vaginal ring
is a matrix-type silicone elastomer product containing 25 mg dap-
ivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI)
with potent activity against HIV-1 in vitro (Fletcher et al., 2009;
Van Herrewege et al., 2004a,b). Based on in vitro studies, reser-
voir-type vaginal rings loaded with 25 mg dapivirine have been re-
ported to release sufﬁcient quantities of dapivirine to provide
in vitro concentrations capable of inhibiting vaginal HIV transmis-
sion (Malcolm et al., 2005; Woolfson et al., 2006a,b). Several Phase
I dapivirine studies have been completed, including the testing of
various vaginal gel formulations (Nel et al., 2009b, 2010a,b) and
a matrix-type and reservoir-type vaginal ring (Nel et al., 2009a; Ro-
mano et al., 2009). The matrix ring entered Phase III testing in
2012.
Standard treatment for HIV/AIDS involves the use of combina-
tion ARVs as part of highly active antiretroviral therapy (HAART).
By using drugs from different therapeutic classes and having differ-
ent mechanisms of action, the virus is targeted at multiple stages of
the infection/replication cycle, which can increase the breadth of
activity and reduce the propensity for emergence of resistant viral
strains (Garg et al., 2009, 2010; Herrera et al., 2009; Martinez et al.,
2006; Pirrone et al., 2011; Ramjee et al., 2011). It is rational to ex-
tend this combination strategy to ARV-based vaginal microbicides
(Herrera et al., 2009; Schader et al., 2011). A combination of emtri-
citabine (nucleoside reverse transcriptase inhibitor) and tenofovir
disoproxil fumarate (nucleotide analogue reverse transcriptase
inhibitor) has already been shown to confer protection (Grant
et al., 2010) and the same combination is currently being investi-
gated as part of VOICE. Other combination microbicide ring prod-
ucts are in the early stages of preclinical development (Johnson
et al., 2010; Moss et al., 2012; Saxena et al., 2009).
Here, we report the pharmaceutical development and testing of
a silicone elastomer vaginal ring formulation that provides con-
trolled release of dapivirine and maraviroc.
2. Materials and methods
2.1. Materials
Dapivirine (micronized) and maraviroc (non-micronized) were
supplied by the International Partnership for Microbicides (Silver
Spring, MD, USA). Medical grade silicone elastomers LSR9-9508-
30 and MED-4870 were purchased from NuSil Technology
(Carpinteria, CA, USA). Both materials are addition-cure,
translucent, rapid-cure, liquid silicone rubber systems supplied
as two-part kits. The parts (Parts A and B) must be mixed to initiate
the curing reaction. LSR9-9508-30 has a lower pre-cure viscosity
and a lower post-cure Shore hardness compared with MED-4870,
and was used during early stage development for ease of injection
molding. MED-4870 is presently used in the manufacture of the
dapivirine-only ring. HPLC-grade water was obtained using a Mil-
lipore Direct-Q 3 UV Ultrapure Water System (Millipore, Watford,
UK). Dichloromethane, HPLC-grade methanol, HPLC-grade acetoni-
trile, potassium dihydrogen orthophosphate (AnalaR analytical re-
agent) and HPLC-grade isopropanol were purchased from VWR
International Ltd. (Dublin, Ireland). Phosphoric acid (85% w/w in
water) and 19-norethindrone (internal standard for HPLC) were
purchased from Sigma–Aldrich (Gillingham, UK) and ammonium
acetate was purchased from Fisher Scientiﬁc (Loughborough, UK).
2.2. Thermal analysis of microbicide-loaded cured silicone elastomer
samples
Samples of cured LSR9-9508-30 silicone elastomer loaded with
either maraviroc (10% w/w), dapivirine (10% w/w) or both marav-
iroc and dapivirine (10% w/w each) were prepared by mixing the
appropriate quantities of each component in a SpeedMixer DAC
150 FVZ-K (Synergy Devices, High Wycombe, UK) (1:1 w/w mix-
ture of Parts A and B, 3500 rpm, 20 s) before curing in an oven
(50 C, 30 min). Differential scanning calorimetry (DSC) analysis
of each silicone sample (35 mg) and the supplied microbicides
(5 mg) was conducted using a calibrated TA Instruments Q100
Differential Scanning Calorimeter (Elstree, UK) in standard heating
ramp mode. Baseline calibration was carried out using an empty
cell and temperature calibration was conducted using cyclopen-
tane and indium standards. Test samples were heated under an
atmosphere of nitrogen (50–300 C, 10 C/min) in closed alumin-
ium pans (TA Instruments, Elstree, UK) (part numbers
900779.901 and 900786.901), alongside an empty reference pan.
2.3. Solubility of dapivirine and maraviroc in cured silicone elastomer
The saturation solubilities of dapivirine and maraviroc in LSR9-
9508-30 and MED-4870 silicone elastomers were determined
using a method described previously (van Laarhoven et al., 2002).
Brieﬂy, silicone elastomer ﬁlms (1.5 mm thick) were prepared from
each elastomer system by combining Parts A and B (1:1 w/w) and
curing (LSR9-9508-30, 24 h at 25 C; MED-4870, 1 h at 150 C) be-
tween glass plates separated by spacers. The cured ﬁlms were cut
into strips (50 mm  50 mm  1.5 mm) and each strip (n = 4 per
elastomer per microbicide) was weighed and placed in a glass ﬂask
containing 100 mL HPLC-grade water. Excess (200 mg) of either
dapivirine or maraviroc was added to each sample and the ﬂasks
were stored in a rotating orbital incubator (Infors HT Unitron, Inf-
ors AG, Bottmingen, Switzerland) for 8 weeks (37 C, 60 rpm) to al-
low drug to saturate the silicone elastomer. Strips were removed
from the ﬂasks, rinsed with HPLC-grade water and blotted dry.
Each strip was cut into small pieces (approximately
5 mm  5 mm  1.5 mm) and reﬂuxed in a mixture comprising
95 mL dichloromethane and 5 mL internal standard solution
(5 mg/mL 19-norethindrone in methanol) for 2 h. A 10 mL aliquot
of the reﬂux solutions were removed and evaporated to dryness
using a BUCHI Syncore Polyvap system (BUCHI UK Ltd., Oldham,
UK), reconstituted in 2 mL acetonitrile, vortexed (30 s), sonicated
(20 min) and then centrifuged (10 min, 2000 rpm). This extraction
method has previously been validated and used to provide com-
plete extraction of the dapivirine and/or maraviroc content from
silicone strips/rings (Nel et al., 2009a; other unpublished data).
The concentration of dapivirine or maraviroc in the ﬁnal solutions
was quantiﬁed by reverse-phase HPLC (Section 2.4) and the data
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used to calculate the solubility of each drug in the silicone
elastomers.
2.4. HPLC analytical method for quantiﬁcation of silicone elastomer
solubility, in vitro release and drug content
HPLC analysis was performed using a Waters HPLC system
(Waters, Dublin, Ireland) consisting of a Waters 1525 Binary HPLC
pump, a Waters 717 Plus Autosampler, a Waters In-line Degasser
AF Unit and a Waters 2487 Dual k Absorbance Detector, along with
Breeze software (Version 3.30). Each sample was injected (25 lL
aliquot) onto a Thermo Scientiﬁc BDS Hypersil C18 column
(150  4.6 mm, 3 lm particle size) (Fisher Scientiﬁc UK Ltd.,
Loughborough, UK) held at 30 C. Gradient elution was performed
using a mobile phase of 10 mM potassium dihydrogen orthophos-
phate (adjusted to pH 3.0 using phosphoric acid) (solvent A) and
acetonitrile (solvent B) with a ﬂow rate of 1.0 mL/min and run time
of 7 min (0.0–4.0 min: 70–20% A; 4–4.5 min: 20–70% A; 4.5–
7.0 min: 70% A). Maraviroc, 19-norethindrone and dapivirine were
detected by UV absorption at 210 nm with retention times of 4.8,
6.3 and 6.6 min, respectively.
2.5. Manufacture of rings for formulation development
Matrix-type, silicone elastomer, human-sized vaginal rings
loaded with 25 mg dapivirine and 25, 50, 100, 200 or 400 mg
maraviroc were manufactured by high temperature reaction injec-
tion moulding. Dapivirine and maraviroc were mixed at the appro-
priate concentrations into both Parts A and B of the platinum-
catalysed silicone elastomer LSR9-9508-30 using a SpeedMixer
(1 min, 3000 rpm). The active mixes were combined (1:1 w/w),
speed-mixed (1 min, 3000 rpm), injected into stainless steel molds
ﬁtted to a laboratory-scale ring-making machine, and cured for
3 min at 80 C. The vaginal rings measured 56.0 and 7.6 mm in
external and cross-sectional diameter, respectively (Fig. 1).
2.6. In vitro release testing of vaginal rings
In vitro release testing over 28 or 29 days was performed for
both LSR9–9508-30 (n = 4, 28 days) and MED-4870 (n = 12 for each
stability storage condition, 29 days) vaginal rings using a sink
condition model. Individual rings were placed into 250 mL DUR-
AN laboratory glass bottles containing 200 mL 1:1 mixture of iso-
propanol/water and stored in an orbital shaking incubator (37 C,
60 rpm, 25 mm orbital throw). The release medium was sampled
and replaced (100 mL) daily with the exception of weekends
(200 mL used to maintain sink conditions). Dapivirine and marav-
iroc concentrations were quantiﬁed by reverse-phase HPLC with
UV detection, as described previously (Section 2.4).
2.7. Manufacture of rings for stability testing
Matrix-type silicone elastomer vaginal rings loaded with
100 mg maraviroc and 25 mg dapivirine were manufactured using
a liquid silicone rubber injection molding machine (Arburg 125V,
Loesburg, Germany). Batches of premix containing appropriate
quantities of dapivirine and maraviroc in Part A of the platinum-
catalysed silicone elastomer MED-4870 were produced using a
paddle blade mixer (60 rpm for 5 min then 100 rpm for 35 min).
Six separate batches of the Part A premix were transferred into a
20 L pail and degassed for 30 min. The same process was repeated
to produce premix in Part B MED-4870. Parts A and B premixes
were separately pumped via a dosing meter (E4-5M, Fluid Automa-
tion, Wixom, MI, USA) through a static mixer (1:1 mix ratio) into
the injection molding machine. The mix was then injected into a
heated stainless steel mold assembly comprising a single ring
shaped cavity (outer diameter 57.6 mm, cross sectional diameter
7.7 mm). Each ring was cured at 140 C for 25 s.
2.8. Testing protocols for ring stability study
Vaginal rings were packaged in semi-permeable, paper-plastic
pouches and stored in stability cabinets (Binder KBF 115 Constant
Climate Chamber, Binder GmbH, Tuttlingen, Germany) maintained
at 30 C/65% relative humidity (RH) or 40 C/75% RH (ICH guide-
lines for accelerated stability studies). At deﬁned monthly time-
points (T0, T1M, T2M, T3M, T6M, etc.), a sample set of 35 active vaginal
rings and three placebo vaginal rings was removed for analysis (Ta-
ble 1). At each time-point, vaginal rings were tested for in vitro re-
lease of maraviroc and dapivirine, mechanical properties, content
assay and the presence of related substances.
2.9. Mechanical testing of rings
Mechanical properties of vaginal rings were assessed at each
time-point (n = 10) by compression testing and measurement of
tensile strength. Compression and tensile testing were performed
using a TA.XTplus Texture Analyser (Stable Micro Systems Ltd.,
Godalming, UK). For compression testing, each vaginal ring was
placed vertically in a specially designed holder ﬁxed to the base-
plate of the Texture Analyser. A probe attached to the movable
Fig. 1. Silicone elastomer vaginal ring containing 25 mg dapivirine and 100 mg
maraviroc. Ring dimensions: 56 mm external diameter, 7.6 mm cross-sectional
diameter.
Table 1
Vaginal ring sample set codes according to storage conditions and time-points for
analysis.
Storage time (months) Storage conditions
30 C/65% RH 40 C/75% RH
0 T0 –
1 T1 (30/65) T1 (40/75)
2 T2 (30/65) T2 (40/75)
3 T3 (30/65) T3 (40/75)
6 T6 (30/65) T6 (40/75)
9 T9 (30/65) –
12 T12 (30/65) –
18 T18 (30/65) –
24 T24 (30/65) –
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arm was used to compress the vaginal ring ﬁve times through a
distance of 5.0 mm (speed 2.0 mm/s) and the maximum compres-
sive force was recorded (in Newtons). For tensile testing, the Tex-
ture Analyser was ﬁtted with a 30 kg load cell and two ring grips
(attached to the base and movable arm of the analyser). Vaginal
rings were stretched at a rate of 10.0 mm/s until rupture. The
pass/fail criterion was set at 5 kg.
2.10. Microbicide content assay of rings
Microbicide content assay was measured for each set of vaginal
rings (n = 10). Vaginal rings were cut into discs (2 mm thickness),
and the dapivirine and maraviroc content extracted using the
method described previously (Section 2.3), with the following
points of difference: 2 mL aliquot of extraction solution was evap-
orated to dryness, reconstituted in 10 mL acetonitrile and diluted
(1 in 2) with HPLC-grade water prior to HPLC analysis (Section 2.4).
2.11. Method for extracting drugs and related substances from rings
Dapivirine and maraviroc related substances in vaginal rings at
each time-point (n = 3) were quantiﬁed by solvent extraction, as
described previously (Section 2.10), with the following points of
difference: reﬂuxed in 100 mL dichloromethane; 25 mL aliquot of
extraction solution was evaporated to dryness, reconstituted in
5 mL acetonitrile and diluted (1 in 5) with acetonitrile and HPLC-
grade water to give a ﬁnal solution with 1:1 composition of each
solvent. Dilutions of each sample (1%) were also prepared for the
purpose of quantitation of unidentiﬁed peaks or identiﬁed impuri-
ties. Placebo vaginal rings were analysed in the same way (n = 3).
2.12. HPLC analytical method for related substances
Reverse-phase HPLC analysis was conducted using a Waters
HPLC system (described previously, Section 2.4) and a Halo C18
column (150  3.0 mm, 2.7 lm particle size) (Wilmington, DE,
USA) held at 40 C. Gradient elution was performed using a mobile
phase of 0.01 M ammonium acetate (pH 5.7) (solvent A) and aceto-
nitrile (solvent B) with a ﬂow rate of 0.38 mL/min and run time of
33 min (0–12 min: 92–60% A; 12–15 min: 60% A; 15–22 min: 60–
35% A; 22–24 min: 35–10% A; 24–25 min: 10% A; 25–26 min: 10–
92% A; 26–33 min: 92% A) (30 lL injection volume). Maraviroc and
dapivirine were detected after 17.8 and 28.2 min at 210 nm and
288 nm, respectively. Standard solutions of known impurities were
prepared and analysed to allow identiﬁcation and quantitation of
related substances where necessary. Samples obtained from pla-
cebo vaginal rings were used to identify peaks attributable to
MED-4870.
2.13. Statistical analysis
Where appropriate, results were statistically analysed using a
one-way ANOVA, followed by Post hoc analysis using the Tukey–
Kramer multiple comparisons test. In all cases, a p value of less
than 0.05 was considered signiﬁcant. Analysis was conducted
using GraphPad Prism.
3. Results
3.1. Thermal analysis of microbicide-loaded cured silicone elastomer
samples
Representative DSC traces for cured silicone elastomer samples
loaded with dapivirine and/or maraviroc, are presented in Fig. 2.
Each trace is annotated with the onset temperature (the lower
temperature), peak temperature (the higher temperature) and en-
thalpy values for all observed melting transitions. The transitions
for dapivirine and maraviroc in the combination ring sample
(Fig. 2A) were similar to those observed in the single active ring
samples (Fig. 2B and C) and also those of the pure actives
(Fig. 2D and E), suggesting no interactions between the two com-
pounds and no evidence of eutectic formation within the cured sil-
icone elastomer system. Eutectic formation has been observed
previously between the active components in the combination
contraceptive NuvaRing (Van Laarhoven et al., 2002).
3.2. Solubility of dapivirine and maraviroc in cured silicone elastomer
Experimentally determined values for the solubility of dapivi-
rine and maraviroc in the cured silicone elastomers fell within
the range 0.21–0.34 mg/g (Table 2), values at least ten-fold lower
than reported previously for etonogestrel and ethinyl estradiol in
ethylene vinyl acetate copolymer (NuvaRing) (van Laarhoven
et al., 2002). The solubility of dapivirine was slightly higher in both
silicone elastomer systems compared with maraviroc, while solu-
bility was signiﬁcantly greater in MED-4870 compared with
LSR9-9508-30. Drug solubility in the silicone elastomer matrix is
a necessary prerequisite for drug release, with the extent of solu-
bility directly inﬂuencing the release rate.
3.3. In vitro release from LSR9-9508-30 vaginal rings
The cumulative in vitro release versus time proﬁles for LSR9-
9508-30 rings are presented in Fig. 3. The release of both maraviroc
and dapivirine increased with increasing maraviroc loading
(Fig. 3A and B, respectively). After 28 days, cumulative maraviroc
release was 5.7, 11.4 and 18.5 mg for rings initially loaded with
25, 100 and 400 mg maraviroc, respectively, clearly illustrating
the effect of drug loading upon release. Dapivirine release (each
ring contained 25 mg dapivirine) was also inﬂuenced by the initial
maraviroc loading, with cumulative release values after 28 days of
9.4, 10.6 and 11.4 mg for rings loaded with 25, 100 and 400 mg
maraviroc, respectively. Linear relationships between cumulative
release and root time were observed for both drugs in all formula-
tions tested (R2 > 0.990, graphs not shown) indicating that release
obeyed t½ kinetics, typical of permeation-controlled polymeric de-
vices containing a dispersion of solid drug (Higuchi, 1961, 1963;
Malcolm et al., 2003a, 2012a; Roseman and Higuchi, 1970).
The increased maraviroc release (Fig. 3A), an effect observed
previously for other drug loaded matrix-type silicone elastomer
devices (Maeda et al., 2002; Malcolm et al., 2003a, 2003b, 2004;
McBride et al., 2009), is entirely expected based on an understand-
ing of the mathematics governing permeation-controlled poly-
meric devices containing a dispersion of solid drug (Malcolm
et al., 2003a, 2012a). The smaller increases in dapivirine release
(Fig. 3B) are directly attributed to the inﬂuence of increasing
maraviroc content in the rings, which modiﬁes the diffusional
characteristics of the silicone elastomer network.
Dapivirine was released in greater quantities than maraviroc
when the loadings of both drugs were equivalent (i.e. 25 mg
maraviroc and 25 mg dapivirine, Table 3), reﬂecting the differing
physicochemical properties of the microbicides (Table 2). For
example, dapivirine has a higher log P value, lower molecular
weight, and higher silicone elastomer solubility compared with
maraviroc, all of which enhance drug permeation (Russell et al.,
2000; Woolfson et al., 1999). The maraviroc release characteristics
were most similar to those of the 25 mg dapivirine ring with
100 mg maraviroc loading (Table 3). This formulation was selected
for further study (and, ultimately, progress to the clinic).
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3.4. Ring stability testing data
Daily and cumulative in vitro release proﬁles at various stability
time points are presented in Fig. 4 for MED-4870 vaginal rings
containing 25 mg dapivirine and 100 mg maraviroc. Although the
maraviroc and dapivirine cumulative release proﬁles (Fig. 4B and
D) show entirely similar trends to those observed previously with
LSR9-9508-30 rings (Fig. 3), some variability is apparent such that
the proﬁles at different stability time points do not overlap each
other. However, as evidenced by the daily release vs. time proﬁles
(Fig. 4A and C), this variation is almost entirely associated with
variability in the ﬁrst day release values, which range from 3.44
to 5.77 mg for maraviroc and 1.19–2.34 mg for dapivirine. Daily re-
lease values on subsequent days were entirely similar across the
stability time points (Fig. 4A and B). For example, there was no sig-
niﬁcant difference in the total mass of maraviroc released at T1M
and T24M (13.4 mg versus 12.3 mg; p > 0.05). The greater variability
associated with maraviroc is most likely attributed to its non-
micronised nature. The broader distribution in particle size of the
solid maraviroc particles present at the ring surface (compared
with micronised dapivirine) will signiﬁcantly inﬂuence initial re-
lease behaviour, as observed previously (our unpublished data).
However, drug release from the vaginal rings again followed t½
kinetics (R2 > 0.989 and 0.997 for maraviroc and dapivirine
respectively).
The compression test data for MED-4870 vaginal rings as a
function of storage time are presented in Fig. 5, where mean com-
pression forces of 2 N are reported. While some variability in the
Fig. 2. DSC traces for ring samples containing dapivirine and maraviroc (A); ring sample containing maraviroc (B); ring sample containing dapivirine (C); maraviroc API (D);
dapivirine API (E). The drug loadings in the DSC samples (10% w/w per active) were signiﬁcantly higher than those in the rings, in order to provide suitably sized thermal
transitions.
Table 2
Physicochemical properties and experimental silicone elastomer solubility data for
dapivirine and maraviroc.
Property Dapivirine Maraviroc
Drug class NNRTI CCR5 entry
inhibitor
MW (g/mol) 329.4 513.7
Experimental unbuffered water
solubility
0.02 lg/mLa 1.03 mg/mLb
Experimental IPA*/water solubility 1.54 mg/
mLc
>50 mg/mLd
Log P +4.6e +2.55b
LSR9-9508-30 solubility (mg/g) 0.26 ± 0.003 0.21 ± 0.031
MED-4870 solubility (mg/g) 0.34 ± 0.061 0.22 ± 0.032
* IPA – isopropanol.
a Fetherston et al. (2012).
b Malcolm et al., 2012a (experimentally determined log P value).
c Woolfson et al., 2006b.
d R.K. Malcolm, unpublished data.
e Woolfson et al., 2006a (calculated log P value).
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compression force at the various stability time-points was ob-
served (a general trend of increased compression force with stor-
age time; 48 out of 78 comparisons measured as signiﬁcantly
different, p < 0.05), the differences were relatively small and al-
most certainly insigniﬁcant in a clinical setting. Storage time did
not affect tensile properties, with all rings withstanding (no rup-
ture) a 5 kg force during tensile testing (data not shown). There
is no clinical/regulatory speciﬁcation for the mechanical properties
of vaginal rings. Similar compression testing of the commercial
vaginal rings Estring, Femring and Nuvaring have been re-
ported previously, with measured compression force values rang-
ing between 3 and 9 N (Promadej-Lanier et al., 2009). The
general impact of drug loading on the mechanical properties of
vaginal rings has also been assessed previously, with increasing so-
lid drug loading producing increased ring compression force
(unpublished data). The 25 mg dapivirine-only ring, currently in
Phase III testing and upon which this dapivirine + maraviroc com-
bination ring is based, has already demonstrated safety in clinical
use (Nel et al., 2009a and other unpublished data). The incorpora-
tion of 100 mg maraviroc into the ring does not signiﬁcantly in-
crease the compression force compared with the dapivirine-only
rings, with values maintained around 2 N.
The mean percentage contents of maraviroc and dapivirine in
MED-4870 vaginal rings relative to the theoretical content (based
on the active loading in premix and the ﬁnal ring weight) at each
time point in the stability study are presented in Fig. 6. Maraviroc
content ranged from 88.1% to 100.0% and dapivirine content from
92.5% to 104.0%. No overall trend in drug content was observed as a
function of storage temperature and humidity.
At each stability time-point, the related substances assay
showed no degradation products or process impurities at levels
high enough to be speciﬁed (i.e. >0.1%), conﬁrming long term sta-
bility of maraviroc and dapivirine in the MED-4870 silicone elasto-
mer rings.
4. Discussion
With a number of single-agent antiretroviral microbicide prod-
ucts having completed or currently undergoing human clinical
testing (Abdool Karim et al., 2010; Nel et al., 2009a,b, 2010a,b; Ro-
mano et al., 2009), attention is now turning to more advanced
strategies, including combination microbicides and multi-purpose
prevention technologies (Johnson et al., 2010; Han et al., 2007;
Moss et al., 2012; Pirrone et al., 2011; Saxena et al., 2009; Schader
et al., 2011; Thurman et al., 2011). The most promising combina-
tion microbicide strategies are those that target multiple steps in
the viral replication cycle, mimicking drug regimes used in highly
active antiretroviral therapy. The low molecular weight and hydro-
phobic characteristics of non-nucleoside reverse transcriptase
inhibitors and CCR5 receptor antagonist entry inhibitors make
them particularly suitable for incorporation into and prolonged
delivery from silicone elastomer vaginal ring devices. All commer-
cial vaginal ring products (Estring, NuvaRing, Femring, Proger-
ing/Fertiring) provide release of one or more steroid molecules,
having similar physicochemical characteristics. The dapivirine sili-
cone elastomer vaginal ring is already well advanced in the clinic,
while the licensed drug maraviroc is effective at reducing viral
loads in infected people and shows promise as a single agent
microbicide (Forbes et al., 2011; Malcolm et al., 2012a, in press;
Neff et al., 2011; Tsibris et al., 2011; Veazey et al., 2005a,b, 2010).
Here, we report for the ﬁrst time a combination microbicide for-
mulation, in the form of a silicone elastomer vaginal ring, providing
simultaneous release of dapivirine and maraviroc. In order to facil-
itate development and regulatory progress, the combination ring
was based on the same design, elastomer material (MED-4870)
and manufacturing method as the current dapivirine-only ring,
although initial formulation development was conducted using sil-
icone elastomer LSR9-9508-30 due to its similarity to MED-4870
and its relative ease of handling and injection molding. Both dap-
ivirine and maraviroc were released from the vaginal rings accord-
ing to a permeation-controlled mechanism, as conﬁrmed by
release proﬁles that followed t1/2 kinetics over the 28- and 29-
day study periods. Consistent with t1/2 kinetics, and widely re-
ported and discussed in the literature for other matrix-type vaginal
rings containing dispersed solid drug particles (Fetherston et al., in
press; Malcolm et al., 2005, 2012a; Nel et al., 2009a; Woolfson
et al., 2003, 2006b), both dapivirine and maraviroc show a rela-
tively high release on day 1 followed by steadily declining release
quantities on subsequent days. Initially, drug concentrations are
highest at the surface of the device, leading to high drug release
rates. As time progresses, drug is depleted from the surface layers,
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Fig. 3. Cumulative release of (A) maraviroc and (B) dapivirine from LSR9-9508-30
vaginal rings containing various loadings of maraviroc. Both axes have the same y-
axis scale, for ease of comparison. The percentage relative standard deviation
associated with the corresponding daily release data was less than 10% (n = 4).
Table 3
Summary of in vitro release data for LSR9-9508-30 vaginal rings containing various
loadings of maraviroc and 25 mg dapivirine.
Maraviroc
loading
(mg)
Day 1
release
(mg)
Day 25
release
(mg)
Cumulative
release after
28 days (mg)
% Release
after
28 days
Daily
release rate
(mg/day0.5)
Mean maraviroc in vitro release (various loadings)
25 1.92 0.087 5.69 22.8 0.86
50 2.35 0.093 7.90 15.8 1.33
100 3.44 0.18 11.40 11.4 1.97
200 4.15 0.24 14.38 7.2 2.55
400 4.57 0.33 18.54 4.6 3.50
Mean dapivirine in vitro release (25 mg loading)
25 3.17 0.12 9.38 37.5 1.34
50 2.95 0.12 9.92 39.7 1.51
100 3.08 0.16 10.64 42.6 1.65
200 3.22 0.13 10.91 43.7 1.71
400 3.18 0.14 11.36 45.4 1.82
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and subsequent release requires the underlying drug to permeate
the depletion zone in the silicone elastomer matrix. The thickness
of the drug depletion zone increases as more and more drug is re-
leased, resulting in declining drug release rates with time. The
cumulative quantity of drug released versus time is effectively
modelled by the Higuchi equation (Higuchi, 1961, 1963) to conﬁrm
permeation controlled, t1/2 release kinetics.
Previous pharmacokinetic studies in women with the 25 mg
matrix-type dapivirine ring provided vaginal tissue and ﬂuid con-
centrations that are considered sufﬁciently high, based on in vitro
activity assays, to potentially provide protection in vivo during a
28-day continuous use regime (Nel et al., 2009a; Romano et al.,
2009). Efﬁcacy data for the 25 mg dapivirine ring will not likely
be reported until 2014, as part of the recently started Phase III
study. The ﬁnal maraviroc loading in the combination ring was se-
lected on the basis of its low nanomolar in vitro activity (similar to
dapivirine) and closely matching the in vitro release proﬁle of the
25 mg dapivirine-only ring. Based on the data presented in Fig. 3,
a 100 mg maraviroc loading was chosen for progress.
In addition to silicone elastomer vaginal rings, various other
vaginal microbicide formulation strategies for dapivirine have
been described previously, including gels (Nel et al., 2009b,
2010a, 2010b; Nuttall et al., 2008), polyurethane vaginal rings
(Gupta et al., 2008; Johnson et al., 2010), and ﬁlms (Akil et al.,
2011). Aqueous hydroxyethylcellulose (HEC) gel formulations of
dapivirine have been shown to be safe and acceptable to women
(Nel et al., 2009b, 2010a, 2010b). Dapivirine is distributed through-
out the vaginal tract when administered in these gels, and studies
in both humans and animals have suggested that once daily
administration of a gel may be sufﬁcient to provide efﬁcacy against
HIV infection (Nel et al., 2010a; Nuttall et al., 2008). Other dapivi-
rine formulations currently in development include quick-dissolv-
ing vaginal ﬁlms for rapid drug release (Akil et al., 2011) and
polyurethane vaginal rings for delivery over a sustained period of
time (Gupta et al., 2008; Johnson et al., 2010). Data from these var-
ious studies support the continued development of dapivirine as a
microbicide.
Maraviroc formulations in development for mucosal adminis-
tration include aqueous HEC gels (Malcolm et al., in press; Neff
et al., 2011; Veazey et al., 2010), silicone elastomer gels (Forbes
et al., 2011) and silicone elastomer vaginal rings (Malcolm et al.,
2012a). Pharmacokinetic studies on maraviroc-loaded HEC gels in
macaques indicate that drug levels measured in vaginal ﬂuid, vag-
inal tissue and plasma increase as the administered dose is in-
creased (Malcolm et al., in press). This formulation has also been
tested for efﬁcacy against a single high-dose vaginal challenge with
SHIV-162P3, with complete protection achieved with a gel
containing 3.3% w/w maraviroc (Malcolm et al., in press; Veazey
et al., 2010). However, an increase in the delay between gel
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application and virus challenge was shown to correlate with a
reduction in protection (Veazey et al., 2010). This timing issue
may be reduced through the use of a silicone elastomer gel formu-
lation, which provides higher levels of maraviroc in vaginal ﬂuid,
vaginal tissue and plasma in macaques than when the equivalent
dose is delivered in a HEC gel, and for a longer period of time (up
to 24 h) (Forbes et al., 2011). Sustained delivery from a vaginal ring
may further increase the duration of protection afforded from the
single application of a microbicide product. A pharmacokinetic
study of maraviroc-loaded silicone elastomer vaginal rings in ma-
caques has demonstrated that this compound is delivered contin-
uously over a 28-day period (Malcolm et al., 2012a). At steady
state, maraviroc concentrations in both vaginal ﬂuid and vaginal
tissue were approximately 106 times greater than the 50% inhibi-
tory concentrations required for in vitro inhibition of SHIV-162P3
in macaque lymphocytes.
Data generated to date on both dapivirine and maraviroc indi-
cate that a silicone elastomer vaginal ring containing both of these
compounds is likely to be safe in humans and may be an effective
formulation for the prevention of HIV infection in women.
Although a range of other formulations are being considered,
which is important from the perspective of providing women with
a range of options according to their own preferences and require-
ments, it is likely that a vaginal ring would be well tolerated by
women and may have improved user-adherence compared to a
gel formulation. Here, the results of the stability study conducted
with the MED-4870 vaginal rings indicated that this formulation
is stable in terms of in vitro release, mechanical properties, assay
content and related substances for 24 months when stored at con-
ditions of elevated temperature and humidity. Given these encour-
aging data, a Phase I trial to assess safety and pharmacokinetics of
this combination ring formulation has recently been completed
and data analysis is in progress.
5. Conclusions
A silicone elastomer matrix-type vaginal ring formulation con-
taining 25 mg dapivirine and 100 mg maraviroc has been devel-
oped. Both microbicides are continuously released in vitro over
29 days and the ring formulation is stable for at least 2 years under
conditions of elevated temperature and humidity. This vaginal ring
may be valuable in preventing sexual HIV transmission to women
during heterosexual intercourse with an infected partner. Although
data are not yet available, the ring was evaluated in a Phase I clin-
ical trial in 2012.
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